Resolvin D1

Resolvin D1

• CAS Number: 872993-05-0
• UNSPSC Description: Resolvin D1 (RvD1), an endogenous pro-resolving mediator of inflammation, is derived from omega-3 docosahexaenoic acid during the resolution phase of acute inflammation. Resolvin D1 blocks proinflammatory neutrophil migration by regulating actin polymerization, reduces TNF-α–mediated inflammation in macrophages, and enhances phagocytosis of apoptotic cells by macrophages[1][2].
• Target Antigen: Endogenous Metabolite
• Type: Natural Products
• Related Pathways: Metabolic Enzyme/Protease
• Applications: COVID-19-immunoregulation
• Field of Research: Inflammation/Immunology
• Assay Protocol: https://www.medchemexpress.com/resolvin-d1.html
• Purity: 99.60
• Solubility: 10 mM in DMSO
• Smiles: CC/C=C\C[C@@H](/C=C/C=C\C=C\C=C\[C@H]([C@H](C/C=C\CCC(O)=O)O)O)O
• Molecular Weight: 376.49
• References & Citations: [1]Schmid M, et al. Resolvin D1 Polarizes Primary Human Macrophages toward a Proresolution Phenotype through GPR32. J Immunol. 2016 Apr 15;196(8):3429-37.|[2]Gao Y, et al. Resolvin D1 Improves the Resolution of Inflammation via Activating NF-κB p50/p50-Mediated Cyclooxygenase-2 Expression in Acute Respiratory Distress Syndrome. J Immunol. 2017 Aug 9. pii: ji1700315.|[3]Benabdoun HA, et al. In vitro and in vivo assessment of the proresolutive and antiresorptive actions of resolvin D1: relevance to arthritis. Arthritis Res Ther. 2019 Mar 12;21(1):72.
• Shipping Conditions: Blue Ice
• Storage Conditions: Solution, -20°C, 2 years
• Clinical Information: No Development Reported